In this pooled analysis, an impressive ORR of 19% derived from anti-PD-1/PD-L1 therapy compared favorably to the ORRs of 7% to 9% from current second-line therapies for advanced NSCLC [24–26]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.